NeuroOne Medical Technologies (NMTC) said Tuesday it has regained compliance with Nasdaq's minimum share price requirement for continued listing.
The company said it was notified by Nasdaq Monday that its bid price deficiency had been cured and NeuroOne was in compliance will all applicable listing standards.
Shares of the company were down 2.2% in recent trading.
Price: 1.06, Change: -0.02, Percent Change: -2.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.